Amyloidosis: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TTR 56
• BCMA 11
• APOE 0
• SGLT2 0
• CD19 4
• MAPT 0
• CD38 0
• TNF 0
• APP 0
• BCL-2 0
• RET 0
• SNCA 0
• TREM2 0
• GPRC5D 2
• IL-1 0
• IL-6 0
• JAK 0
• LAG-3 0
• PPAR 0
• BACE1 0
• CFTR 0
• CXCR4 0
• EGFR 0
• HIF-1 0
• NRF2 0
• PARP 0
• PI3K 0
• TLR4 0
• TP53 0

24 of 82+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NHLBI · K23

  TARGET-TTR: Targeted Artificial Intelligence-Driven Screening of Transthyretin Amyloid Cardiomyopathy in the Electronic Health Record

  Yale University· New Haven, United States· US$170,964 awarded in fiscal year 2026· until Jul 2031

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Curation, Integration, Modelling and Rational Design of Small Molecule Amyloid Inhibitors (AmyStoppers)

  Vilniaus Universitetas· Vilnius, Lithuania· EU contribution €196,976· until Mar 2029

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Unravelling the Role of Cerebral Amyloid-beta Angiopathy in Epilepsy: Inflammatory Pathways and Interneuron Dysfunction (EPICAA)

  Ludwig-Maximilians-Universitaet Muenchen· Planegg, Germany· EU contribution €217,965· until Feb 2029

• European Commission (Horizon Europe) · HORIZON-ERC

  The Mechanisms of neuronal silencing in Alzheimer’s Disease – investigation of cellular and network mechanisms in mouse models of β-amyloidosis (MONSil-AD)

  Klinikum Der Technischen Universität München (Tum Klinikum)· Muenchen, Germany· EU contribution €1,482,666· until Dec 2030

• European Commission (Horizon 2020) · ERC-COG

  A unified drug discovery platform for protein misfolding diseases (ProMiDis)

  Erevnitiko Kentro Vioiatrikon Epistimon Alexandros Flemingk· Vari-Athens, Greece· EU contribution €1,972,000· until Feb 2027

5 of 5 running projects, newest first. Listed amounts together: US$171.0k + €3.9m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Open-Label Study of AG10 in Patients With Cardiomyopathy

  NCT03536767· Eidos Therapeutics, a BridgeBio company· Updated 14 Oct 2026

  “Study ended by the sponsor due to meeting Study Objectives”Registry text, quoted unchanged. Source

• Withdrawn

  ION-682884 in Patients With TTR Amyloid Cardiomyopathy

  NCT04843020· Brigham and Women's Hospital· Updated 20 Feb 2026

  “no subjects available”Registry text, quoted unchanged. Source

• Terminated

  Transthyretin Amyloidosis Cardiomyopathy in Patients With HFpEF in Russia

  NCT06338839· AstraZeneca· Updated 18 Sept 2025

  “The study was suspended after interim analysis to confirm reasonability of further investigation of the population”Registry text, quoted unchanged. Source

• Withdrawn

  Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records

  NCT04569903· Yale University· Updated 18 Sept 2025

  “No patients consented to enrollment”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of AG10 in Subjects with Transthyretin Amyloid Polyneurophathy

  NCT04418024· Eidos Therapeutics, a BridgeBio company· Updated 19 Sept 2024

  “After a careful review of the currently available treatments worldwide for patients with ATTR-polyneuropathy, Eidos has made the decision to halt the current study design.”Registry text, quoted unchanged. Source

• Withdrawn

  Efficacy and Safety of Acoramidis (AG10) in Subjects with Transthyretin Amyloid Polyneurophathy (ATTRibute-PN)

  NCT04882735· Eidos Therapeutics, a BridgeBio company· Updated 19 Sept 2024

  “Sponsor's decision to cancel study”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy

  2024-518343-38-00· Alnylam Pharmaceuticals Inc.· Source

• Southeastern ATTR Amyloidosis Consortium: SEATTRAC Family Registry

  NCT05974644· Virginia Commonwealth University· Source

• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Alnylam Pharmaceuticals· Source

• PET/CT Imaging in Carriers of TTR Mutations

  NCT07591038· University of Texas Southwestern Medical Center· Source

• Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Alexion Pharmaceuticals, Inc.· Source

• A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Alnylam Pharmaceuticals· Source

• CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

  NCT07207811· Novo Nordisk A/S· Source

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Alnylam Pharmaceuticals· Source

• A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

  NCT06260709· Novo Nordisk A/S· Source

• TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy

  NCT07223203· Alnylam Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Mendelian Randomization Analysis 1
• CRISPR-Cas Systems 3
• Gene Expression Profiling 3
• Sequence Analysis, RNA 3
• Exome Sequencing 3
• Proteomics 20
• Metabolomics 2
• Mass Spectrometry 14
• Flow Cytometry 1
• Immunohistochemistry 14
• Positron-Emission Tomography 33
• Magnetic Resonance Imaging 95
• Machine Learning 13
• Deep Learning 4
• Cohort Studies 42
• Genome-Wide Association Study 2

• Proteomic dysregulation associated with cerebral amyloid angiopathy.

  Alzheimers Dement, Oct 2026

• Bioepidemiology of cardiac amyloidosis.

  Cardiovasc Pathol, Jul 2026

• Proteomic profiling of whole tissue sections in cardiac ATTR amyloidosis reveals increased extracellular matrix remodeling.

  Cardiovasc Pathol, Jun 2026

• Ectopic Insulin-Derived Amyloidosis Arising in the Inguinal Region Distant From Injection Sites.

  J Dermatol, Jun 2026

• Blood-based proteomic signature of amyloidosis: identification of novel regulators of amyloid load.

  Alzheimers Dement, Jun 2026

• Three-Dimensional Visualization and Proteomic Analysis of Human Cardiac Transthyretin Amyloidosis Tissue Reveals Microangiopathy and Capillary Occlusion.

  J Am Heart Assoc, May 2026

• A rare case of renal AHL amyloidosis with marked complement deposition: clinicopathologic and proteomic findings.

  BMC Nephrol, Apr 2026

• CMV titer associations with cognition and the plasma proteome implicate FLT1 and neurovascular mechanisms as potential moderators.

  J Neuroinflammation, Apr 2026

• AIns (insulin) type amyloidosis in a kidney transplant candidate with a newly identified monoclonal gammopathy.

  J Hematop, Mar 2026

• Application of Omics Analysis in the Clinical Practice and Research of Transthyretin Amyloidosis.

  Genes (Basel), Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.